Stock On Watch: Time to Buy Intra-Cellular Therapies Inc After Making 52 Week Low?

Stock On Watch: Time to Buy Intra Cellular Therapies Inc After Making 52 Week Low?

The stock of Intra-Cellular Therapies Inc (NASDAQ:ITCI) hit a new 52-week low and has $11.95 target or 9.00% below today’s $13.13 share price. The 7 months bearish chart indicates high risk for the $550.98M company. The 1-year low was reported on Oct, 17 by If the $11.95 price target is reached, the company will be worth $49.59M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 370,522 shares traded hands. Intra-Cellular Therapies Inc (NASDAQ:ITCI) has declined 52.98% since March 14, 2016 and is downtrending. It has underperformed by 58.59% the S&P500.

Analysts await Intra-Cellular Therapies Inc (NASDAQ:ITCI) to report earnings on November, 3. They expect $-0.81 EPS, up 10.99% or $0.10 from last year’s $-0.91 per share. After $-0.71 actual EPS reported by Intra-Cellular Therapies Inc for the previous quarter, Wall Street now forecasts 14.08% negative EPS growth.

Intra-Cellular Therapies Inc (NASDAQ:ITCI) Ratings Coverage

Out of 8 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 6 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 75% are positive. Intra-Cellular Therapies has been the topic of 15 analyst reports since August 6, 2015 according to StockzIntelligence Inc. As per Thursday, September 17, the company rating was maintained by Guggenheim. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, November 6. On Thursday, September 29 the stock rating was downgraded by JMP Securities to “Market Perform”. The firm has “Neutral” rating given on Thursday, September 29 by SunTrust. The stock has “Market Outperform” rating given by JMP Securities on Wednesday, March 9. Piper Jaffray initiated the stock with “Overweight” rating in Thursday, June 2 report. As per Friday, August 7, the company rating was upgraded by Zacks.

According to Zacks Investment Research, “Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.”

Insitutional Activity: The institutional sentiment increased to 1.71 in Q2 2016. Its up 0.25, from 1.46 in 2016Q1. The ratio is positive, as 17 funds sold all Intra-Cellular Therapies Inc shares owned while 28 reduced positions. 23 funds bought stakes while 54 increased positions. They now own 30.01 million shares or 2.84% more from 29.18 million shares in 2016Q1.
Gilder Gagnon Howe & Co Ltd Liability Corp owns 300,952 shares or 0.23% of their US portfolio. The Connecticut-based Cubist Systematic Strategies Limited Liability Corporation has invested 0% in Intra-Cellular Therapies Inc (NASDAQ:ITCI). Geode Mngmt Ltd Limited Liability Company holds 0% or 220,799 shares in its portfolio. Northern Trust Corporation has 0% invested in the company for 392,471 shares. Tiaa Cref Invest Mngmt Limited Liability Corp accumulated 151,266 shares or 0% of the stock. Senzar Asset Mngmt Limited Liability Co owns 144,624 shares or 0% of their US portfolio. Blackrock holds 0.01% or 104,029 shares in its portfolio. Gam Holding Ag accumulated 61,400 shares or 0.04% of the stock. Driehaus Cap Ltd accumulated 93,536 shares or 0.13% of the stock. Moreover, Wasatch Advsr Inc has 0.48% invested in Intra-Cellular Therapies Inc (NASDAQ:ITCI) for 811,812 shares. Keybank Natl Association Oh owns 5,554 shares or 0% of their US portfolio. Eam Lc, a California-based fund reported 20,737 shares. Tekla Capital Management Ltd Liability Com, a Massachusetts-based fund reported 187,800 shares. Wells Fargo And Communications Mn accumulated 0% or 11,641 shares. Bb Biotech Ag holds 1.07% of its portfolio in Intra-Cellular Therapies Inc (NASDAQ:ITCI) for 700,000 shares.

More important recent Intra-Cellular Therapies Inc (NASDAQ:ITCI) news were published by: which released: “Why Intra-Cellular Therapies Inc. Is Crashing Today” on September 29, 2016, also published article titled: “Intra-Cellular Therapies (ITCI) Alert: Shareholder Rights Law Firm Johnson …”, published: “Intra-Cellular Therapies shares plunge 68% after study results” on September 28, 2016. More interesting news about Intra-Cellular Therapies Inc (NASDAQ:ITCI) was released by: and their article: “Intra-Cellular Therapies Shares Plunge After Disappointing Drug Trial Results” with publication date: September 28, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: ,

Leave a Comment